Molecular Basis of Reduced Pyridoxine 5′-Phosphate Oxidase Catalytic Activity in Neonatal Epileptic Encephalopathy Disorder
about
The human flavoproteomeMolecular mechanisms of disease-causing missense mutationsThe structure of a Xanthomonas general stress protein involved in citrus canker reveals its flavin-binding propertyExperimental Evidence for a Revision in the Annotation of Putative Pyridoxamine 5'-Phosphate Oxidases P(N/M)P from Fungi.Genome-wide association analysis of genetic generalized epilepsies implicates susceptibility loci at 1q43, 2p16.1, 2q22.3 and 17q21.32.Salmonella typhimurium PtsJ is a novel MocR-like transcriptional repressor involved in regulating the vitamin B6 salvage pathway.Proteomic profiling reveals that resveratrol inhibits HSP27 expression and sensitizes breast cancer cells to doxorubicin therapyEpilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome.Pyridoxine responsiveness in novel mutations of the PNPO gene.Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions.Typical and atypical phenotypes of PNPO deficiency with elevated CSF and plasma pyridoxamine on treatment.Lysine acetylation regulates the activity of Escherichia coli pyridoxine 5'-phosphate oxidase.Inactive mutants of human pyridoxine 5'-phosphate oxidase: a possible role for a noncatalytic pyridoxal 5'-phosphate tight binding site.Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer.Biochemical data from the characterization of a new pathogenic mutation of human pyridoxine-5'-phosphate oxidase (PNPO).
P2860
Q27008969-D81D9C3C-8AD3-4BD3-A5A3-8449567388C0Q27021940-A9F9F9E8-765F-4BE1-85A4-5CA8BDC36638Q27681685-AA1BE52A-9253-4E6E-A95F-48EC07C9E5D1Q27936433-26A39236-4DBB-4228-9210-5402167B8FA9Q29417109-3D0BCA0C-C0F4-42B2-9D5C-7BA2115CCD64Q33283406-23018FE1-D14D-4FC0-ACBD-7EE6955F29BAQ36877600-57874C6A-EE3F-46E8-9480-E8D832AE8CC2Q37723424-4589FAA5-1221-4B5A-8C50-F52A6360DF73Q37725884-C672606A-D611-4813-A483-C015466C5EB5Q38061207-0CA3C372-D945-44A5-B17C-2623640C257DQ38165237-950BA6B1-E64C-4D40-9524-A0377612D12AQ39049184-21F65153-38BA-46C7-A6DF-55527A2CC2E0Q40988277-02BA7B35-88E5-4B7D-877B-5B666B57CF59Q47295997-CC753B98-4CE3-491E-ADA5-F0DEF977BC9FQ49590380-1E458E47-3F9C-453F-89E3-18E84B0388E2
P2860
Molecular Basis of Reduced Pyridoxine 5′-Phosphate Oxidase Catalytic Activity in Neonatal Epileptic Encephalopathy Disorder
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Molecular Basis of Reduced Pyr ...... leptic Encephalopathy Disorder
@ast
Molecular Basis of Reduced Pyr ...... leptic Encephalopathy Disorder
@en
Molecular Basis of Reduced Pyr ...... leptic Encephalopathy Disorder
@nl
type
label
Molecular Basis of Reduced Pyr ...... leptic Encephalopathy Disorder
@ast
Molecular Basis of Reduced Pyr ...... leptic Encephalopathy Disorder
@en
Molecular Basis of Reduced Pyr ...... leptic Encephalopathy Disorder
@nl
prefLabel
Molecular Basis of Reduced Pyr ...... leptic Encephalopathy Disorder
@ast
Molecular Basis of Reduced Pyr ...... leptic Encephalopathy Disorder
@en
Molecular Basis of Reduced Pyr ...... leptic Encephalopathy Disorder
@nl
P2093
P2860
P3181
P356
P1476
Molecular basis of reduced pyr ...... leptic encephalopathy disorder
@en
P2093
Alexina Haynes
Faik N Musayev
Mario A Saavedra
Martin K Safo
Mohini S Ghatge
Verne Schirch
P2860
P304
30949-30956
P3181
P356
10.1074/JBC.M109.038372
P407
P577
2009-09-15T00:00:00Z